²é¿´: 1410  |  »Ø¸´: 8
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

angelhunte

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

²ËÄñ

[ÇóÖú] »ÔÈðÐÂÉÏÊеÄÐÂÒ©crizotinibµÄALKøÒÖÖÆÂÊÊǶàÉÙ£¬Èç¹ûÓÐÎÄÏ×»á×·¼Ó100½ð±Ò

»ÔÈðÐÂÉÏÊеÄÐÂÒ©crizotinibµÄALKøÒÖÖÆÂÊÊǶàÉÙ£¬Èç¹ûÓÐÎÄÏ×»á×·¼Ó100½ð±Ò
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

Çó¹¤×÷
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

juanjuanweixiao

ľ³æ (ÖøÃûдÊÖ)

¡ï
³ÕÒÄ×ÓÆ¤: ½ð±Ò+1, лл½»Á÷£¬»¶Ó­³£À´Å¶¡£ 2012-09-20 08:33:26
ÕâÁ½ÕÅ±í¶¼ÊÇFDAÉ걨×ÊÁÏÀïµÄ£¬Äã¿ÉÒÔÏÂÀ´¿´¿´

1.jpg



2.jpg

8Â¥2012-09-20 00:16:37
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 9 ¸ö»Ø´ð

songxiangen

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
³ÕÒÄ×ÓÆ¤: ½ð±Ò+1, лл½»Á÷£¬»¶Ó­³£À´Å¶¡£ 2012-09-20 08:32:53
Crizotinib (PF-02341066) µÄÉúÎï»îÐÔ
Inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK(nucleophosmin-anaplastic lymphoma kinase) fusion protein.[1] A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as NPM-ALK has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL). [2]
After incubation with Crizotinib (PF-02341066), cells were washed once with HBSS supplemented with 1 mmol/L Na3VO4 and protein lysates were generated. Subsequently, phosphorylation of ALK was assessed by a sandwich ELISA method using an immobilized anti¨Ctotal-ALK antibody and an anti¨Cphospho-ALK antibody (pY1604) as a detec ion antibody.
Crizotinib (PF-02341066) inhibited NPM-ALKphosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value=24 nM).
Crizotinib (PF-02341066) potently inhibited cell proliferation, which was associated with G1-S¨Cphase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC50 values=30 nM) but not ALK-negative lymphoma cells. The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase¨Cmediated nick-end labeling and Annexin V staining (IC50 values=25¨C50 nM). [3]

Crizotinib (PF-02341066) ²Î¿¼ÎÄÏ×
[1] Blood 2005;105: 2640-2653
[2] Oncogene 2001;20:5623-5637
[3] Mol Cancer Ther 2007;6:3314-3322

²»ÖªµÀ¶ÔÂ¥Ö÷ÓÐûÓÐÓÃ
2Â¥2012-09-18 11:35:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

angelhunte

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

²ËÄñ

ÒýÓûØÌû:
2Â¥: Originally posted by songxiangen at 2012-09-18 11:35:33
Crizotinib (PF-02341066) µÄÉúÎï»îÐÔ
Inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK(nucleophosmin-anaplastic lymphoma kinase) fusion protein. A t(2;5) chromosomal translocation r ...

ϸ°û»îÐÔ£¬ÎÒÒªµÄÊÇø»îÐÔ£¬Óб¨µÀ˵СÓÚ1nM,µ«²»ÖªµÀ¾ßÌåÊý¾Ý
Çó¹¤×÷
3Â¥2012-09-18 15:02:27
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

С¶¬¹ÏÝæÝæ

Òø³æ (³õÈëÎÄ̳)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
angelhunte: ½ð±Ò+8, ¡ïÓаïÖú, ÖÁÉÙ˵Ã÷ÄúÈÏÕæ¿´¹ý 2012-09-18 22:37:21
³ÕÒÄ×ÓÆ¤: ½ð±Ò+2, лл½»Á÷£¬»¶Ó­³£À´Å¶¡£ 2012-09-20 08:32:59
»¹ÊÇÎÒÀ´Ó¦´ð°É£¡
crizotinibµÄALKøÒÖÖÆÂÊ99%£¨1΢Ħ¶ûŨ¶ÈÏ£©£¬ALKøÒÖÖÆIC50СÓÚ1nm¡£
²Î¿¼ÎÄÏ×£ºJournal of Medicinal chemistry 2011£¬ 54£¬ 6342-6363£¨Table¡£5.£©
4Â¥2012-09-18 16:41:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 279·ÖÇóµ÷¼Á Ò»Ö¾Ô¸211 +9 chaojifeixia 2026-03-19 9/450 2026-03-20 11:54 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷ÄϽ»Í¨ ר˶ ²ÄÁÏ355 ±¾¿ÆË«·Ç Çóµ÷¼Á +4 Î÷ÄϽ»Í¨×¨²Ä355 2026-03-19 4/200 2026-03-20 11:39 by »¨¿ª¸»¹óÐÒ¸£ÈËÉ
[¿¼ÑÐ] 286·ÖÈ˹¤ÖÇÄÜרҵÇëÇóµ÷¼ÁÔ¸Òâ¿ç¿¼£¡ +3 lemonzzn 2026-03-17 4/200 2026-03-20 11:04 by lemonzzn
[¿¼ÑÐ] 271²ÄÁϹ¤³ÌÇóµ÷¼Á +7 .6lL 2026-03-18 7/350 2026-03-20 09:10 by xingguangj
[¿¼ÑÐ] 281Çóµ÷¼Á£¨0805£© +11 ÑÌÏ«Ò亣 2026-03-16 21/1050 2026-03-20 08:45 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Çóµ÷¼Á +3 °µÓ¿afhb 2026-03-16 3/150 2026-03-20 00:28 by ºÓÄÏ´óѧУÓÑ
[ÂÛÎÄͶ¸å] ÉêÇë»Ø¸åÑÓÆÚÒ»¸öÔ£¬±à¼­Í¬ÒâÁË¡£µ«ÏµÍ³ÉϵÄʱ¼äû±ä£¬¸ø±à¼­ÓÖдÓʼþÁË£¬Ã»»Ø¸´ 10+3 wangf9518 2026-03-17 4/200 2026-03-19 23:55 by babero
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +5 February_Feb 2026-03-19 5/250 2026-03-19 23:51 by 23Postgrad
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйúº£Ñó´óѧ£¬ÉúÎïѧ£¬301·Ö£¬Çóµ÷¼Á +5 1ËïÎò¿Õ 2026-03-17 6/300 2026-03-19 23:46 by zcl123
[¿¼ÑÐ] Çóµ÷¼Á +3 Mqqqqqq 2026-03-19 3/150 2026-03-19 14:11 by peike
[¿¼ÑÐ] 346Çóµ÷¼Á[0856] +3 WayneLim327 2026-03-16 6/300 2026-03-19 11:21 by WayneLim327
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á +7 С²Ä»¯±¾¿Æ 2026-03-18 7/350 2026-03-19 10:46 by Linda Hu
[¿¼ÑÐ] 304Çóµ÷¼Á +6 ˾¿Õ. 2026-03-18 6/300 2026-03-18 23:03 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 0854£¬¼ÆËã»úÀàÕÐÊÕµ÷¼Á +3 ºúÀ±ÌÀ·ÅÌÇ 2026-03-15 6/300 2026-03-18 12:09 by Éϰ¶Éϰ¶¡­¡­..
[¿¼ÑÐ] 280Çóµ÷¼Á +6 ¹¾ààÏþÏþ 2026-03-18 7/350 2026-03-18 11:25 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 268Çóµ÷¼Á +6 ¼òµ¥µã0 2026-03-17 6/300 2026-03-18 09:04 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] ²ÄÁÏר˶326Çóµ÷¼Á +6 Ä«ìÏæ¦Ý· 2026-03-15 7/350 2026-03-17 17:10 by ruiyingmiao
[¿¼ÑÐ] 277²ÄÁÏ¿ÆÑ§Ó빤³Ì080500Çóµ÷¼Á +3 ×ÔÓɼå±ý¹û×Ó 2026-03-16 3/150 2026-03-16 14:10 by ÔËÆøyunqi
[¿¼ÑÐ] 0856ר˶279Çóµ÷¼Á +5 ¼ÓÓͼÓÓÍ£¡? 2026-03-15 5/250 2026-03-15 11:58 by 2020015
[¿¼ÑÐ] 330Çóµ÷¼Á +3 ?½´¸øµ÷¼Á¹òÁË 2026-03-13 3/150 2026-03-14 10:13 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û